CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

被引：0
|
作者：
H S Wasan
G M Springett
C Chodkiewicz
R Wong
J Maurel
C Barone
B Rosbrook
A D Ricart
S Kim
J-P Spano
机构：
[1] Hammersmith Hospital,Department of Cancer Medicine
[2] H. Lee Moffitt Cancer Center and Research Institute,undefined
[3] Cancer Care Manitoba,undefined
[4] St. Boniface General Hospital,undefined
[5] Hospital Clinic de Barcelona,undefined
[6] CIBEREHD,undefined
[7] Catholic University Sacro Cuore,undefined
[8] Pfizer Oncology,undefined
[9] Science Center Drive,undefined
[10] Hôpital de la Pitié Salpêtrière,undefined
[11] 47–83 Boulevard de l'Hôpital,undefined
[12] 75651,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
advanced pancreatic cancer; CA 19-9; biomarkers; axitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1162 / 1167
页数：5
相关论文
共 50 条
  • [21] Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
    Yang-Yang Ma
    Yin Leng
    Yan-Li Xing
    Hong-Mei Li
    Ji-Bing Chen
    Li-Zhi Niu
    World Journal of Clinical Cases, 2020, 8 (22) : 5564 - 5575
  • [22] Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy
    Bauer, Todd M.
    El-Rayes, Bassel F.
    Li, Xiaobai
    Hammad, Nazik
    Philip, Philip A.
    Shields, Anthony F.
    Zalupski, Mark M.
    Bekaii-Saab, Tanios
    CANCER, 2013, 119 (02) : 285 - 292
  • [23] CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy
    Heilbrun, L. K.
    Khanna, A.
    Venkatramanamoorthy, R.
    Shields, A. F.
    Philip, P. A.
    Zalupski, M. M.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
    Heinemann, Volker
    Quietzsch, Detlef
    Gieseler, Frank
    Gonnermann, Michael
    Schoenekaes, Herbert
    Rost, Andreas
    Neuhaus, Horst
    Haag, Caroline
    Clemens, Michael
    Heinrich, Bernard
    Vehling-Kaiser, Ursula
    Fuchs, Martin
    Fleckenstein, Doris
    Gesierich, Wolfgang
    Uthgenannt, Dirk
    Einsele, Hermann
    Holstege, Axel
    Hinke, Axel
    Schalhorn, Andreas
    Wilkowski, Ralf
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3946 - 3952
  • [25] Analysis of axitinib (AG-013736) plus gemcitabine in patients with advanced pancreatic cancer: Diastolic blood pressure as biomarker of clinical benefit
    Spano, J.
    Maurel, J.
    Wasan, H.
    Bycott, P.
    Liau, K.
    Pithavala, Y.
    Garrett, M.
    Ricart, A.
    Kim, S.
    Chockiewicz, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 11 - 11
  • [26] CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy.
    Patel, B
    Heilburn, L
    Khanna, A
    Venkatramanamoorthy, R
    Shields, A
    Philip, P
    Zalupski, M
    El-Rayes, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 355S - 355S
  • [27] Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
    Loehr, J. M.
    Haas, S. L.
    Bechstein, W. -O.
    Bodoky, G.
    Cwiertka, K.
    Fischbach, W.
    Foelsch, U. R.
    Jaeger, D.
    Osinsky, D.
    Prausova, J.
    Schmidt, W. E.
    Lutz, M. P.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1214 - 1222
  • [28] Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
    Loehrer, Patrick J., Sr.
    Feng, Yang
    Cardenes, Higinia
    Wagner, Lynne
    Brell, Joanna M.
    Cella, David
    Flynn, Patrick
    Ramanathan, Ramesh K.
    Crane, Christopher H.
    Alberts, Steven R.
    Benson, Al B., III
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4105 - 4112
  • [29] Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study
    Inal, A.
    Kos, F. T.
    Algin, E.
    Yildiz, R.
    Berk, V.
    Unek, I. Tugba
    Colak, D.
    Kucukoner, M.
    Elkiran, E. Tamer
    Helvaci, K.
    Geredeli, C.
    Dane, F.
    Balakan, O.
    Kaplan, M. Ali
    Durnali, A. Gok
    Harputoglu, H.
    Goksel, G.
    Ozdemir, N.
    Buyukberber, S.
    Gumus, M.
    Ozkan, M.
    Benekli, M.
    Isikdogan, A.
    JOURNAL OF BUON, 2012, 17 (01): : 102 - 105
  • [30] Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
    Bendell, J.
    O'Reilly, E. M.
    Middleton, M. R.
    Chau, I.
    Hochster, H.
    Fielding, A.
    Burke, W.
    Burris, H., III
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 804 - 811
12345